Quest Diagnostics Incorporated

NYSE:DGX Aktierapport

Börsvärde: US$21.1b

Quest Diagnostics Framtida tillväxt

Future kriterier kontrolleras 1/6

Quest Diagnostics förväntas öka intäkter och intäkter med 9.9% respektive 4.3% per år. EPS förväntas tillväxt med 9.6% per år. Avkastningen på eget kapital förväntas bli 16% om 3 år.

Viktig information

9.9%

Tillväxttakt i vinsten

9.58%

Tillväxttakt för EPS

Healthcare vinsttillväxt18.3%
Intäkternas tillväxttakt4.3%
Framtida avkastning på eget kapital16.02%
Bevakning av analytiker

Good

Senast uppdaterad18 May 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Uppdatering av berättelse • May 13

DGX: Refreshed 2026 Outlook And Margin Assumptions Will Sustain Safe Haven Appeal

Quest Diagnostics' analyst price target has been revised to $223.25 from $218.19 as analysts factor in recent target increases across the Street and updated assumptions around discount rate, profit margins and future P/E multiples. Analyst Commentary Recent Street research around Quest Diagnostics has centered on refreshed valuation work and price target changes, with several firms adjusting their numbers based on updated assumptions for discount rates, profit margins and future P/E multiples.
Seeking Alpha • May 07

Quest Diagnostics: Updating Levels After Q1 Earnings

Summary Quest Diagnostics delivered strong Q1 results with 9.2% revenue growth and 13% EPS growth, driving management to raise 2026 guidance. DGX's growth is fueled by advanced diagnostics, robust consumer and hospital channels, and efficiency gains from AI and automation. Key risks include margin pressure from lower-priced partnership volumes and potential Medicare reimbursement cuts under PAMA. I maintain a 5/5 conviction rating, raising my Buy Threshold to $197 and holding the Sell Target at $227, reflecting confidence in DGX's long-term outlook. Read the full article on Seeking Alpha
Uppdatering av berättelse • Apr 20

DGX: Organic Guidance And Capital Returns Will Sustain Safe Haven Appeal

Analyst price targets for Quest Diagnostics have been adjusted slightly lower to $218.19 from $218.50, as analysts factor in updated views on revenue growth, profit margins, and long term P/E assumptions following a series of recent target changes across the coverage universe. Analyst Commentary Recent research updates point to a mixed but generally constructive stance on Quest Diagnostics, with multiple target changes and one fresh list inclusion helping to frame how analysts are thinking about valuation, execution, and growth risk.
Uppdatering av berättelse • Apr 05

DGX: Organic Guidance And Capital Returns Will Support Safe Haven Profile

Analysts have raised their price targets on Quest Diagnostics by between $5 and $30, largely pointing to recently issued organic revenue growth guidance and viewing the broader diagnostic lab space as a relative safe haven within healthcare services. Analyst Commentary Recent Street research around Quest Diagnostics and its closest peer highlights a constructive setup for the broader diagnostic lab group, with price target moves on Quest generally framed against views that the sector can act as a relative safe haven within healthcare services.
Uppdatering av berättelse • Mar 22

DGX: Premium Multiple And Capital Returns Look Supported By Organic Revenue Guidance

Analysts have raised their price targets on Quest Diagnostics by a range of $5 to $30, citing the company’s recent organic revenue growth guidance and viewing the diagnostic testing space as a relative safe haven within healthcare services. Analyst Commentary Recent research on Quest Diagnostics highlights a cluster of higher price targets and an upgrade, with many investors treating large diagnostic labs as a relatively defensive corner of healthcare services.
Uppdatering av berättelse • Mar 07

DGX: Fair Outlook As Premium Multiple And Capital Returns Shape Future Earnings

Analysts raised their price target on Quest Diagnostics by about $1 to $218.50, reflecting refined assumptions that include slightly higher revenue growth, a similar discount rate, modestly adjusted profit margins, and a small change in future P/E expectations, supported by broadly positive recent research across the diagnostic lab space. Analyst Commentary Street research around Quest Diagnostics has focused on how the company is positioned within the broader diagnostic lab group, with recent moves in peer guidance and a series of price target changes shaping sentiment on both upside potential and execution risk.
Uppdatering av berättelse • Feb 21

DGX: Fair Outlook As Higher Payouts And Consumer Labs Support Future Earnings

Analysts have lifted their price target on Quest Diagnostics by about $18, reflecting slightly higher modeled revenue growth and a somewhat richer future P/E assumption, even as projected profit margins are trimmed in line with recent Street research that has broadly raised targets across the lab testing group. Analyst Commentary Bullish analysts have broadly raised their price targets on Quest Diagnostics, reflecting a more constructive view on the lab testing group as a whole and on Quest's positioning within it.
Uppdatering av berättelse • Feb 06

DGX: Fair Outlook As Consumer Lab Partnerships And Margins Support Future Earnings

Analysts have inched up their fair value estimate for Quest Diagnostics to about $199 per share, a move they tie to slightly higher margin and P/E assumptions following recent research that points to potential upside to current earnings estimates. Analyst Commentary Recent Street research points to potential upside to current earnings estimates for Quest Diagnostics, which is feeding into a more constructive view on the stock’s valuation and execution risk.
Uppdatering av berättelse • Jan 23

DGX: Future Consumer Lab Partnerships And Neurology Tests Will Support Balanced Outlook

Analysts have inched up their price target on Quest Diagnostics to about $198.38 from roughly $198.06, reflecting refreshed assumptions around slightly higher revenue growth, a small adjustment to profit margins, and a near steady forward P/E outlook. What's in the News Hims & Hers Health is offering lab testing that it views as a potential US$1b business, with customers accessing testing through Quest Diagnostics and then receiving results and care plans through the Hims platform (Wall Street Journal).
Uppdatering av berättelse • Jan 06

DGX: Future Lab Partnerships And Testing Pipeline Will Support Bullish Outlook

Analysts lifted their price target for Quest Diagnostics by about US$1 to roughly US$198, citing recent Q3 results with sales and earnings ahead of consensus; raised full year guidance; firm organic volume trends; and growing interest in longer term opportunities, such as the Haystack MRD test and a generally supportive lab testing backdrop. Analyst Commentary Street research following the Q3 report points to a generally constructive tone, with multiple firms lifting their price targets and highlighting both execution on current fundamentals and potential longer term growth drivers.
Uppdatering av berättelse • Dec 14

DGX: Future Lab Partnerships And Testing Pipeline Will Support Balanced Outlook

Analysts have nudged their price targets on Quest Diagnostics higher by between $5 and $25 per share, citing solid Q3 outperformance, raised guidance, and confidence in organic growth and future testing catalysts. Analyst Commentary Street research following the Q3 print highlights a generally constructive stance on Quest Diagnostics, with most price target increases framed around stronger than expected fundamentals and improving visibility into growth drivers over the next two years.
Uppdatering av berättelse • Nov 29

DGX: Future Volume Gains And Lab Partnerships Will Support Balanced Outlook

The analyst price target for Quest Diagnostics was modestly increased to $197.31 from $197.25. Analysts cited stronger-than-expected earnings, raised guidance, and continued positive core trends as the rationale for the update.
Uppdatering av berättelse • Nov 15

DGX: Future Revenue Expansion And Partnerships Will Balance Near-Term Risks

Quest Diagnostics saw its analyst price target increase, with several firms now projecting new targets between $195 and $215 per share. Analysts cite strong quarterly results and ongoing positive momentum in core business trends.
Uppdatering av berättelse • Nov 01

DGX: Core Volume Momentum And New Blood Tests Will Drive Share Momentum

Quest Diagnostics' analyst fair value estimate has been raised from $191.56 to $197.25 per share. This change reflects analysts' upbeat outlook after strong quarterly results, improved profit margins, and continued momentum in core business trends.
Uppdatering av berättelse • Oct 18

Preventive Diagnostics And Automation Will Shape Future Healthcare

Analysts have raised their fair value estimate for Quest Diagnostics from $188.19 to $191.56 per share, citing ongoing stable end markets and improving revenue growth expectations. Analyst Commentary Recent street research has highlighted a mix of optimism and caution surrounding Quest Diagnostics.
Analysartikel • Aug 20

Earnings Not Telling The Story For Quest Diagnostics Incorporated (NYSE:DGX)

Quest Diagnostics Incorporated's ( NYSE:DGX ) price-to-earnings (or "P/E") ratio of 21.6x might make it look like a...
Analysartikel • Jun 21

Return Trends At Quest Diagnostics (NYSE:DGX) Aren't Appealing

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
Seeking Alpha • Jan 28

Quest Diagnostics: Good Growth Prospects, But Little To No Upside Left At Current Valuation

Summary Quest Diagnostics' is reporting good numbers for the last 3 quarters, indicating the end of its dull period, which started post COVID. The street and management are expecting mid-single-digit topline growth and high-single-digit bottom-line growth. However, I have a rather moderate opinion on future top-line and bottom-line performance given the poor execution track record and higher leverage, limiting inorganic growth potential. Based on my fair value estimates, the company does not offer substantial upside from here. Read the full article on Seeking Alpha
Seeking Alpha • Oct 24

Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat

Summary Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS, beating Street expectations. The company raised its 2024 revenue guidance and expects significant growth from recent and upcoming acquisitions, projecting double-digit revenue growth for Q4. Despite risks like economic downturns and inflation, I maintain a bullish outlook on DGX, adjusting my Buy Threshold to $150 and Sell Target to $227. DGX's technical indicators and seasonality trends support a bullish trend, prompting me to stay vigilant on trading behavior to capitalize on growth opportunities. Read the full article on Seeking Alpha

Prognoser för vinst- och omsättningstillväxt

NYSE:DGX - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/202812,8831,3231,4221,99711
12/31/202712,3771,1901,3301,90416
12/31/202611,8541,0921,4521,86716
3/31/202611,2781,0201,3261,850N/A
12/31/202511,0359881,3591,886N/A
9/30/202510,8509631,3931,885N/A
6/30/202510,5229451,2241,678N/A
3/31/202510,1588921,0561,494N/A
12/31/20249,8728669091,334N/A
9/30/20249,5398381,0231,397N/A
6/30/20249,3468368751,248N/A
3/31/20249,2878429471,332N/A
12/31/20239,2528508641,272N/A
9/30/20239,2977595961,079N/A
6/30/20239,4887908781,374N/A
3/31/20239,6037898641,332N/A
12/31/20229,8839421,3141,718N/A
9/30/202210,2941,2301,4641,865N/A
6/30/202210,5821,4791,5521,924N/A
3/31/202210,6791,8741,6021,982N/A
12/31/202110,7881,9881,8302,233N/A
9/30/202111,0462,1751,8722,293N/A
6/30/202111,0582,2382,1712,594N/A
3/31/202110,3351,7942,0682,489N/A
12/31/20209,4371,4251,5872,005N/A
9/30/20208,3611,1011,3841,812N/A
6/30/20207,5317498161,249N/A
3/31/20207,6577717791,215N/A
12/31/20197,726835N/A1,243N/A
9/30/20197,639709N/A1,190N/A
6/30/20197,572707N/A1,293N/A
3/31/20197,538720N/A1,295N/A
12/31/20187,531733N/A1,200N/A
9/30/20187,557860N/A1,228N/A
6/30/20187,524808N/A1,188N/A
3/31/20187,469782N/A1,159N/A
12/31/20177,402769N/A1,175N/A
9/30/20177,398671N/A1,156N/A
6/30/20177,427701N/A1,095N/A
3/31/20177,469702N/A1,112N/A
12/31/20167,214642N/A1,116N/A
9/30/20167,503675N/A1,037N/A
6/30/20167,498825N/A948N/A
3/31/20167,517748N/A922N/A
12/31/20157,493706N/A821N/A
9/30/20157,527703N/A852N/A
6/30/20157,551491N/A911N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: DGX s prognostiserade vinsttillväxt ( 9.9% per år) är över sparkvoten ( 3.5% ).

Resultat vs marknad: DGX s intäkter ( 9.9% per år) förväntas växa långsammare än marknaden för US ( 16.8% per år).

Höga tillväxtresultat: DGX s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: DGX s intäkter ( 4.3% per år) förväntas växa långsammare än marknaden för US ( 11.6% per år).

Hög tillväxtintäkter: DGX s intäkter ( 4.3% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: DGX s avkastning på eget kapital förväntas bli låg om 3 år ( 16 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/20 17:13
Aktiekurs vid dagens slut2026/05/20 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Quest Diagnostics Incorporated bevakas av 36 analytiker. 16 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Jasper HellwegArgus Research Company
Eric ColdwellBaird
Luke SergottBarclays